[1] DIWAN A,DIBBS Z,NEMOTO S,et al.Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes[J].Circulation,2004,109(2):262-268.
[2] BOZKURT B,KRIBBS S B,CLUBB F J Jr,et al.Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats[J].Circulation,1998,97(14):1382-1391.
[3] LI Y Y,FENG Y Q,KADOKAMI T,et al.Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosisfactor alpha canbe modulated by anti-tumor necrosis factor alpha therapy[J].Proc Natl Acad Sci U S A,2000,97(23):12746-12751.
[4] COLETTA A P,CLARK A L,BANARJEE P,et al.Clinical trials update:RENEWAL (RENAISSANCE and RECOVER) and ATTACH[J].Eur J Heart Fail,2002,4:559-561.
[5] CHUNG E S,PACKER M,LO K H,et al.Anti-TNF Therapy Against Congestive Heart Failure Investigators.Randomized,double-blind,placebo-controlled,pilot trial of infliximab,a chimeric monoclonal antibody to tumor necrosis factor-alpha,in patients with moderate-to-severe heart failure:results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial[J].Circulation,2003,107:3133-3140.
[6] VANDENABEELE P,DECLERCQ W,BEYAERT R,et al.Two tumour necrosis factor receptors:structure and function[J].Trends Cell Biol,1995,5(10):392-399.
[7] MARTI C N,KHAN H,MANN D L,et al.Soluble tumor necrosis factor receptors and heart failure risk in older adults:Health,Aging,and Body Composition (Health ABC) Study[J].Circ Heart Fail,2014,7(1):5-11.
[8] GARLIE J B,HAMID T,GU Y,et al.Tumor necrosis factor receptor 2 signaling limits β-adrenergic receptor-mediated cardiac hypertrophy in vivo[J].Basic Res Cardiol,2011,106(6):1193-1205.
[9] MVLLER-RISCHART A K,PILSLl A,BEAUDETTE P,et al.The E3 ligase parkin maintains mitochondrial integrity by in- creasing linear ubiquitination of NEMO[J].Mol Cell,2013,49(5):908-921.
[10] DRABAREK B,DYMKOWSKA D,SZCZEPANOWSKA J,et al.TNFα affects energy metabolism and stimulates biogenesis of mitochondria in EA.hy926 endothelial cells[J].Int J Biochem Cell Biol,2012,44(9):1390-1397.
[11] ZHANG Y,ZHANG J,BUTLER J,et al.Contemporary epidemiology,management,and outcomes of patients hospitalized for heart failure in China:results from the China heart failure (China-HF) registry[J].J Card Fail,2017,23(12):868-875.
[12] YANCY C W,JESSUP M,BOZKURT B,et al.2017 ACC / AHA / HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation,2017,136(6):e137-161.
[13] MARÍN-GARCÍA,AKHMEDOV A T.Mitochondrial dynamics and cell death in heart failure[J].Heart Fail Rev,2016,21(2):123-136.
[14] CHEN L,GONG Q,STICE J P,et al.Mitochondrial OPA1,apoptosis,and heart failure[J].Cardiovasc Res,2009,84(1):91-99.
[15] FREZZA C,CIPOLAT S,MARTINS DE BRITO O,et al.OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion[J].Cell,2006,126(1):177-189.
[16] LAFORGE M,RODRIGUES V,SILVESTRE R,et al.NF-κBpathway controls mitochondrial dynamics[J].Cell Death Differ,2016,23(1):89-98.
[17] HAN A,LU Y,ZHENG Q,et al.Qiliqiangxin attenuates cardiac remodeling via inhibition of TGF-β1/Smad3 and NF-κB signaling pathways in a rat model of myocardial infarction[J].Cell Physiol Biochem,2018,45(5):1797-1806.
[18] JIN J L,LV R G,GUO J,et al.Improvement of left ventricular remodelling by inhibition of NF-κB in a rat model of myocardial infarction[J].Heart Lung Circ,2016,25(10):1007-1101.
[19] BROWN D A,PERRY J B,ALLEN M E,et al.Expert consensus document:Mitochondrial function as a therapeutic target in heart failure[J].Nat Rev Cardiol,2017,14(4):238-250. |